Literature DB >> 20651229

Ovarian cancer development and metastasis.

Ernst Lengyel1.   

Abstract

The biology of ovarian carcinoma differs from that of hematogenously metastasizing tumors because ovarian cancer cells primarily disseminate within the peritoneal cavity and are only superficially invasive. However, since the rapidly proliferating tumors compress visceral organs and are only temporarily chemosensitive, ovarian carcinoma is a deadly disease, with a cure rate of only 30%. There are a number of genetic and epigenetic changes that lead to ovarian carcinoma cell transformation. Ovarian carcinoma could originate from any of three potential sites: the surfaces of the ovary, the fallopian tube, or the mesothelium-lined peritoneal cavity. Ovarian cacinoma tumorigenesis then either progresses along a stepwise mutation process from a slow growing borderline tumor to a well-differentiated carcinoma (type I) or involves a genetically unstable high-grade serous carcinoma that metastasizes rapidly (type II). During initial tumorigenesis, ovarian carcinoma cells undergo an epithelial-to-mesenchymal transition, which involves a change in cadherin and integrin expression and up-regulation of proteolytic pathways. Carried by the peritoneal fluid, cancer cell spheroids overcome anoikis and attach preferentially on the abdominal peritoneum or omentum, where the cancer cells revert to their epithelial phenotype. The initial steps of metastasis are regulated by a controlled interaction of adhesion receptors and proteases, and late metastasis is characterized by the oncogene-driven fast growth of tumor nodules on mesothelium covered surfaces, causing ascites, bowel obstruction, and tumor cachexia.

Entities:  

Mesh:

Year:  2010        PMID: 20651229      PMCID: PMC2928939          DOI: 10.2353/ajpath.2010.100105

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  100 in total

Review 1.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

2.  Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases.

Authors:  E Daraï; J Y Scoazec; F Walker-Combrouze; N Mlika-Cabanne; G Feldmann; P Madelenat; F Potet
Journal:  Hum Pathol       Date:  1997-08       Impact factor: 3.466

Review 3.  Precursors to pelvic serous carcinoma and their clinical implications.

Authors:  Ann K Folkins; Elke A Jarboe; Michael H Roh; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2009-02-23       Impact factor: 5.482

4.  Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer.

Authors:  S A Cannistra; C Ottensmeier; J Niloff; B Orta; J DiCarlo
Journal:  Gynecol Oncol       Date:  1995-08       Impact factor: 5.482

5.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers.

Authors:  Kathleen Hibbs; Keith M Skubitz; Stefan E Pambuccian; Rachael C Casey; Kathryn M Burleson; Theodore R Oegema; Jeannine J Thiele; Suzanne M Grindle; Robin L Bliss; Amy P N Skubitz
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 6.  Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.

Authors:  Hilary A Kenny; Songuel Dogan; Marion Zillhardt; Anirban K Mitra; S Diane Yamada; Thomas Krausz; Ernst Lengyel
Journal:  Cancer Treat Res       Date:  2009

7.  Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H.

Authors:  S A Cannistra; G S Kansas; J Niloff; B DeFranzo; Y Kim; C Ottensmeier
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

8.  Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells.

Authors:  Tsutomu Imai; Akiko Horiuchi; Cuiju Wang; Kenji Oka; Satoshi Ohira; Toshio Nikaido; Ikuo Konishi
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

9.  Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination.

Authors:  Natalie M Moss; Maria V Barbolina; Yueying Liu; Limin Sun; Hidayatullah G Munshi; M Sharon Stack
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

10.  Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts.

Authors:  D Tarin; J E Price; M G Kettlewell; R G Souter; A C Vass; B Crossley
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

View more
  655 in total

1.  Ovarian Cells Have Increased Proliferation in Response to Heparin-Binding Epidermal Growth Factor as Collagen Density Increases.

Authors:  Kaitlin C Fogg; Carine M Renner; Hannah Christian; Alyssa Walker; Leilani Marty-Santos; Aisha Khan; Will R Olson; Carl Parent; Andrea O'Shea; Deneen M Wellik; Paul S Weisman; Pamela K Kreeger
Journal:  Tissue Eng Part A       Date:  2020-06-25       Impact factor: 3.845

2.  Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells.

Authors:  Mijung Kim; Lisa Rooper; Jia Xie; Andre A Kajdacsy-Balla; Maria V Barbolina
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

3.  Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models.

Authors:  Robert Clark; Venkatesh Krishnan; Michael Schoof; Irving Rodriguez; Betty Theriault; Marina Chekmareva; Carrie Rinker-Schaeffer
Journal:  Am J Pathol       Date:  2013-08       Impact factor: 4.307

4.  Ovarian cancer spheroids use myosin-generated force to clear the mesothelium.

Authors:  Marcin P Iwanicki; Rachel A Davidowitz; Mei Rosa Ng; Achim Besser; Taru Muranen; Melissa Merritt; Gaudenz Danuser; Tan A Ince; Tan Ince; Joan S Brugge
Journal:  Cancer Discov       Date:  2011-07       Impact factor: 39.397

5.  Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers.

Authors:  Penelope M Drake; Birgit Schilling; Richard K Niles; Akraporn Prakobphol; Bensheng Li; Kwanyoung Jung; Wonryeon Cho; Miles Braten; Halina D Inerowicz; Katherine Williams; Matthew Albertolle; Jason M Held; Demetris Iacovides; Dylan J Sorensen; Obi L Griffith; Eric Johansen; Anna M Zawadzka; Michael P Cusack; Simon Allen; Matthew Gormley; Steven C Hall; H Ewa Witkowska; Joe W Gray; Fred Regnier; Bradford W Gibson; Susan J Fisher
Journal:  J Proteome Res       Date:  2012-03-13       Impact factor: 4.466

6.  Ectopic expressed long non-coding RNA H19 contributes to malignant cell behavior of ovarian cancer.

Authors:  Zhijie Zhu; Ling Song; Jun He; Yanan Sun; Xiaomei Liu; Xiaoyan Zou
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 7.  Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression.

Authors:  H Chkourko Gusky; J Diedrich; O A MacDougald; I Podgorski
Journal:  Obes Rev       Date:  2016-07-19       Impact factor: 9.213

8.  An Unlikely Route: Metastatic Ovarian Malignancy within the Duodenum.

Authors:  Sindhura Kolli; Simcha Weissman; Saad Saleem; Owen T M Chan; Maria Ver; Richard Inae; Mel A Ona
Journal:  Gastrointest Tumors       Date:  2019-09-04

9.  Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.

Authors:  Hadil Onallah; Liora Jacobs Catane; Claes G Tropé; Thea E Hetland Falkenthal; Reuven Reich; Ben Davidson
Journal:  Virchows Arch       Date:  2018-07-21       Impact factor: 4.064

10.  Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.

Authors:  Shreya Raghavan; Maria R Ward; Katelyn R Rowley; Rachel M Wold; Shuichi Takayama; Ronald J Buckanovich; Geeta Mehta
Journal:  Gynecol Oncol       Date:  2015-04-22       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.